Holds inaugural meeting with prominent physicians, scientists and advocacy groups
TORONTO, June 27, 2019 /CNW/ - Pure Global Cannabis Inc. (TSX.V: PURE; OTC: PRCNF; FRA: 1QS) ("Pure Global"), an integrated growth-oriented sciences and consumer products cannabis company, operating through its wholly-owned subsidiary PureSinse Inc. ("PureSinse" or "Company"), recently completed a very successful, inaugural PureSinse Medical Advisory Committee (PMAC) meeting with a number of prominent physicians and scientists from various disciplines. The meeting provided deep insights into the physicians' daily practice, how cannabis impacts their prescribing, and how PureSinse can differentiate in medical and pharma drug development categories.
This first PMAC meeting brought together members representing a variety of different disciplines and facets of the medical committee. As a group, committee members provided direct feedback to inform and guide PureSinse's decision-making in allocating resources to high-need and underserved markets. Members are practicing physicians in primary care, oncology, infectious diseases, psychiatry, and other specialties. The committee also has non-voting members who act as patient representatives, and community and pharmacy industry representatives.
Pure Global CEO & President, Malay Panchal said, "We are very pleased to be able to assemble a very high calibre Medical Advisory Committee, created to receive direct feedback and advice on developing our strategies for the medical cannabis sector. The feedback will be invaluable in creating our educational, outreach programs that provide guidance on medical cannabis use for physicians and patients. The committee deliberations will also help us focus our clinical medical priorities and offer guidance on engagement activities to support the medical community."
Bringing together their wealth of medical and industry experience, PMAC works to provide strategic direction and recommendations to the PureSinse Executive Leadership Team (ELT). The ongoing support of PMAC will cement PureSinse as a trusted provider of education, products, and services for medical cannabis users and prescribers. Direct input and guidance from PMAC will also work to establish PureSinse as a unique brand, grounded in trust and commitment to patients and the medical community.
This meeting of PMAC demonstrated that there is a large demand, and need, for education on the medical benefits of cannabis. PureSinse will use this guidance to tailor educational resources, which provide medical evidence of these benefits, for patients and clinicians. PureSinse will also create an ambassador and mentorship program with a goal to help physicians learn about medical cannabis on a peer-to-peer basis.
Mr. Panchal added: "As more patients become interested in adding medical cannabis to their treatment options, these types of educational resources will continue to be in high demand. Building our brand around trust and education is a key driver in forming PMAC, and continuing our outreach strategy."
About Pure Global Cannabis
Pure Global Cannabis Inc. is an innovation-based cannabis company led by experienced pharma, biotechnology, horticultural, and consumer packaged goods (CPG) experts. The Company's wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Cannabis Act. The Company's Brampton campus houses facilities for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution. Pure Global will produce branded and white-labeled cannabis products for the medical, pharmaceutical, wellness, health & beauty, natural health, food & beverage, craft, and recreational legal markets with uniquely formulated and purified concentrates and dried flower. The Company is using the Canadian market as a springboard to develop and manufacture GMP-compliant premium quality cannabis products for international sale and distribution with a goal to become one of the most trusted premium international cannabis brands.
This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global's future plans and intentions. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Pure Global Cannabis Inc.
For further information: Stephen Pynn, VP Corporate Development, Telephone: 1-866-840-PURE (7873), E-mail: [email protected]; Malay Panchal, President & CEO, Telephone: 1-866-840-PURE (7873), E-mail: [email protected]